Thus, it is unclear how the IRA will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
All entries for: Chronic Disease
May 12, 2026
Nkarta, Inc.
Neutral Outlook
South San Francisco, California
51-200 employees
The effect of the IRA on our business and the healthcare industry in general is not yet known, but we continue to evaluate its potential impact.
Disease Area: Chronic Disease, Immune Diseases, Rare Diseases
Drug Type: Biologic
May 7, 2026
Aligos Therapeutics, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, but is likely to be significant.
Disease Area: Chronic Disease, Infectious Diseases, Metabolic Diseases
Drug Type: Small Molecule
May 7, 2026
Gilead Sciences, Inc.
Negative Outlook
Foster City, CA
10,000+ employees
While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 5, 2026
Biomarin Pharmaceuticals Inc
Neutral Outlook
San Rafael, CA
1000-5000 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
May 4, 2026
Axsome Therapeutics, Inc.
Negative Outlook
New York, NY
201-500 employees
We are evaluating what effect, if any, the IRA may have on our business. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.
Disease Area: Chronic Disease, Neurological Diseases
Drug Type: Small Molecule
April 30, 2026
Ardelyx
Neutral Outlook
Waltham, MA
201-500 employees
While the impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Cardiology, Chronic Disease, Gastrointestinal, Metabolic Diseases, Multiple
Drug Type: Small Molecule
March 23, 2026
Avalo Therapeutics
Neutral Outlook
Wayne, PA
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.
Disease Area: Chronic Disease, Dermatology, Immune Diseases
Drug Type: Biologic, Small Molecule
March 23, 2026
Chemomab Therapeutics
Neutral Outlook
Tel Aviv, Israel
51-200 employees
In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs that have been on the market for at least 7 years and biologics that have been on the market for at least 11 years, and, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements; requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation; and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes.
Disease Area: Chronic Disease, Immune Diseases, Respiratory Diseases
Drug Type: Biologic